A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 20 Dec 2016
At a glance
- Drugs Paclitaxel (Primary) ; HM 30181A
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Athenex
- 15 Dec 2016 Status changed from active, no longer recruiting to completed.
- 08 Mar 2016 Planned End Date changed from 1 Nov 2015 to 1 May 2016, according to ClinicalTrials.gov record.
- 08 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.